Inhibitors of AKT Kinase Increase LDL Receptor MRNA Expression by Two Different Mechanisms

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Jun 20

PMID 31216345

Citations 3

Authors

Katrine Bjune

Lene Wierod

Soheil Naderi

Affiliations

Soon will be listed here.

Abstract

Protein kinase B (AKT) is a serine/threonine kinase that functions as an important downstream effector of phosphoinositide 3-kinase. We have recently shown that MK-2206 and triciribine, two highly selective AKT inhibitors increase the level of low density lipoprotein receptor (LDLR) mRNA which leads to increased amount of cell-surface LDLRs. However, whereas MK-2206 induces transcription of the LDLR gene, triciribine stabilizes LDLR mRNA, raising the possibility that the two inhibitors may actually affect other kinases than AKT. In this study, we aimed to ascertain the role of AKT in regulation of LDLR mRNA expression by examining the effect of five additional AKT inhibitors on LDLR mRNA levels. Here we show that in cultured HepG2 cells, AKT inhibitors ARQ-092, AKT inhibitor VIII, perifosine, AT7867 and CCT128930 increase LDLR mRNA levels by inducing the activity of LDLR promoter. CCT128930 also increased the stability of LDLR mRNA. To study the role of AKT isoforms on LDLR mRNA levels, we examined the effect of siRNA-mediated knockdown of AKT1 or AKT2 on LDLR promoter activity and LDLR mRNA stability. Whereas knockdown of either AKT1 or AKT2 led to upregulation of LDLR promoter activity, only knockdown of AKT2 had a stabilizing effect on LDLR mRNA. Taken together, these results provide strong evidence for involvement of AKT in regulation of LDLR mRNA expression, and point towards the AKT isoform specificity for upregulation of LDLR mRNA expression.

Citing Articles

Identification of an variant in a Chinese familial hypercholesterolemia and its relation to ROS/NLRP3-Mediated pyroptosis in hepatic cells.

Cheng W, Wang W, Deng A, Dang X, Liu C, Wang X J Geriatr Cardiol. 2023; 20(5):341-349.

PMID: 37397863 PMC: 10308174. DOI: 10.26599/1671-5411.2023.05.003.

Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1α Expression.

Li S, Feng F, Deng Y Diabetes Metab Syndr Obes. 2023; 16:1063-1074.

PMID: 37090841 PMC: 10115207. DOI: 10.2147/DMSO.S403893.

Triciribine attenuates pathological neovascularization and vascular permeability in a mouse model of proliferative retinopathy.

Shan S, Liu F, Ford E, Caldwell R, Narayanan S, Somanath P Biomed Pharmacother. 2023; 162:114714.

PMID: 37080089 PMC: 10208444. DOI: 10.1016/j.biopha.2023.114714.

References

Iacovides D, Johnson A, Wang N, Boddapati S, Korkola J, Gray J . Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay. Mol Cell Proteomics. 2013; 12(11):3210-20. PMC: 3820934. DOI: 10.1074/mcp.M112.023119. View

Pinton G, Manente A, Angeli G, Mutti L, Moro L . Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS One. 2012; 7(5):e36856. PMC: 3349630. DOI: 10.1371/journal.pone.0036856. View

Bellacosa A, Testa J, Moore R, Larue L . A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther. 2004; 3(3):268-75. DOI: 10.4161/cbt.3.3.703. View

Bjune K, Sundvold H, Leren T, Naderi S . MK-2206, an allosteric inhibitor of AKT, stimulates LDLR expression and LDL uptake: A potential hypocholesterolemic agent. Atherosclerosis. 2018; 276:28-38. DOI: 10.1016/j.atherosclerosis.2018.07.009. View

Tan S, Ng Y, James D . Next-generation Akt inhibitors provide greater specificity: effects on glucose metabolism in adipocytes. Biochem J. 2011; 435(2):539-44. DOI: 10.1042/BJ20110040. View

Brown M, Radhakrishnan A, Goldstein J . Retrospective on Cholesterol Homeostasis: The Central Role of Scap. Annu Rev Biochem. 2017; 87:783-807. PMC: 5828883. DOI: 10.1146/annurev-biochem-062917-011852. View

Yap T, Walton M, Hunter L, Valenti M, Brandon A, Eve P . Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther. 2010; 10(2):360-71. PMC: 4944842. DOI: 10.1158/1535-7163.MCT-10-0760. View

Krycer J, Sharpe L, Luu W, Brown A . The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab. 2010; 21(5):268-76. DOI: 10.1016/j.tem.2010.01.001. View

Yu Y, Savage R, Eathiraj S, Meade J, Wick M, Hall T . Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015; 10(10):e0140479. PMC: 4607407. DOI: 10.1371/journal.pone.0140479. View

10.

Blumenberg M . Differential transcriptional effects of EGFR inhibitors. PLoS One. 2014; 9(9):e102466. PMC: 4153546. DOI: 10.1371/journal.pone.0102466. View

11.

Manning B, Cantley L . AKT/PKB signaling: navigating downstream. Cell. 2007; 129(7):1261-74. PMC: 2756685. DOI: 10.1016/j.cell.2007.06.009. View

12.

Oh J, Choi Y, Kim J, Park J, Kim S, Park K . Inhibition of low density lipoprotein receptor expression by long-term exposure to phorbol ester via p38 mitogen-activated protein kinase pathway. J Cell Biochem. 2005; 96(4):786-94. DOI: 10.1002/jcb.20551. View

13.

Hua X, Yokoyama C, Wu J, Briggs M, Brown M, Goldstein J . SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc Natl Acad Sci U S A. 1993; 90(24):11603-7. PMC: 48032. DOI: 10.1073/pnas.90.24.11603. View

14.

Yang L, Dan H, Sun M, Liu Q, Sun X, Feldman R . Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004; 64(13):4394-9. DOI: 10.1158/0008-5472.CAN-04-0343. View

15.

Richardson P, Eng C, Kolesar J, Hideshima T, Anderson K . Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012; 8(5):623-33. PMC: 4467022. DOI: 10.1517/17425255.2012.681376. View

16.

Holla O, Strom T, Cameron J, Berge K, Leren T . A chimeric LDL receptor containing the cytoplasmic domain of the transferrin receptor is degraded by PCSK9. Mol Genet Metab. 2009; 99(2):149-56. DOI: 10.1016/j.ymgme.2009.09.012. View

17.

Colgan S, Tang D, Werstuck G, Austin R . Endoplasmic reticulum stress causes the activation of sterol regulatory element binding protein-2. Int J Biochem Cell Biol. 2007; 39(10):1843-51. DOI: 10.1016/j.biocel.2007.05.002. View

18.

WILSON G, Vasa M, Deeley R . Stabilization and cytoskeletal-association of LDL receptor mRNA are mediated by distinct domains in its 3' untranslated region. J Lipid Res. 1998; 39(5):1025-32. View

19.

Ramanathan R, McDonough S, Kennecke H, Iqbal S, Baranda J, Seery T . Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer. 2015; 121(13):2193-7. PMC: 4589423. DOI: 10.1002/cncr.29363. View

20.

Pak Y, Kanuck M, Berrios D, Briggs M, Cooper A, Ellsworth J . Activation of LDL receptor gene expression in HepG2 cells by hepatocyte growth factor. J Lipid Res. 1996; 37(5):985-98. View